SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($2.63), $0.03 better than the analyst estimate of ($2.66). Revenue for the quarter came in at $1.09 million versus the consensus estimate of $890 thousand.

“We have created a novel drug company successfully able to convert our chemical equity into a rich pipeline of clinical assets that are new chemical entities, not repurposed molecules,” said Jeff Jonas, M.D., chief executive officer at Sage Therapeutics. “Even in the face of the difficulties currently challenging the world, I’m pleased to report that the team at Sage is executing across all three brain health franchises and we expect to report on numerous catalysts in the next 18 months.”

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.